Financial results
With Austedo running and the Uzedy launch underway, Teva is beginning to show indications of improvement
SG Tylor
With a fresh growth strategy in place and two successful recent launches, Teva seems to be stepping into a new ...
GSK lowers short-term hopes for RSV treatment Arexvy but raises 2023 forecast
SG Tylor
Great expectations surround GSK’s entry into the respiratory syncytial virus (RSV) vaccine market with their upcoming shot, Arexvy, set to ...
